Elahere approved in Canada for hard-to-treat ovarian cancer
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is…
Gynecological cancer encompasses a group of cancers affecting the female reproductive system. Approximately 100,000 people are diagnosed with gynecological cancer in the U.S. every year. Although each type of gynecological cancer is unique, with its own symptoms, risk factors, and treatment options, reaching an early diagnosis is critical for ensuring the best possible outcomes in any of them.
Read moreThere are several treatment approaches for gynecological cancer, which encompasses all cancers that originate in the female reproductive system. The choice of treatment will depend on the cancer type, how far it has spread, a patient’s general health status, and other factors, such as whether the patient wishes for their fertility to be preserved.
Read moreThe gynecological cancer therapy Elahere (mirvetuximab soravtansine) is…
The U.S. Food and Drug Administration (FDA) has awarded…
September is Gynecologic Cancer Awareness Month, and advocacy…
The U.S. Food and Drug Administration (FDA) has given…
A Phase 3 clinical trial testing the experimental cancer-killing…
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010,…